Stocks News

LAST PRICE
51.3200
TODAY'S CHANGE (%)
Trending Down-0.4100 (-0.7926%)

Bid / Lots
51.0000/ 1
Ask / Lots
52.4700/ 6
Open / Previous Close
51.5200 / 51.7300
Day Range
Low 51.1800
High 51.6200
52 Week Range
Low 45.1300
High 58.9700
Volume
1,283,694
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 6, 2024
- Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment, from 4:13AM ET on Wednesday Nov 06, 2024 by MT Newswires
  4:13AM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: REGN, SNY
  04:13 AM EST, 11/06/2024 (MT Newswires) -- Sanofi (SNY) said Wednesday that the European Medicines Agency has approved its drug Dupixent to treat eosinophilic esophagitis in children from one year of age. Approval for the drug, also called dupilumab...
- Dupixent(R) (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis, from 1:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  1:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: REGN, SNY
  
  All trademarks mentioned in this press release are the property of the Sanofi group apart from VelociSuite and Regeneron Genetics Center.
  Regeneron Contacts: Media Relations Investor Relations Hannah Kwagh Mark Hudson Tel: +1 914-847-6314 Tel: +1 914-847-3482 Hannah.Kwagh@regeneron.com Mark.Hudson@regeneron.com Sanofi Contacts: Investor Relations Media Relations Thomas Kudsk Larsen Sandrine Guendoul Tel: +44 7545 513 693 Tel: +33 6 25 09 14 25 Thomas.Larsen@sanofi.com Sandrine.Guendoul@sanofi.com Alizé Kaisserian Evan Berland Tel: +33 6 47 04 12 11 Tel: +1 215-432-0234 Alize.Kaisserian@sanofi.com Evan.Berland@sanofi.com Arnaud Delépine Victor Rouault Tel: +33 6 73 69 36 93 Tel: +33 6 70 93 71 40 Arnaud.Delepine@sanofi.com Victor.Rouault@sanofi.com Felix Lauscher Timothy Gilbert Tel: +1 908-612-7239 Tel: +1 516-521-2929 Felix.Lauscher@sanofi.com Timothy.Gilbert@sanofi.com Keita Browne Tel: +1 781-249-1766 Keita.Browne@sanofi.com Nathalie Pham Tel: +33 7 85 93 30 17 Nathalie.Pham@sanofi.com Tarik Elgoutni Tel: +1 617-710-3587 Tarik.Elgoutni@sanofi.com Thibaud Châtelet Tel: +33 6 80 80 89 90 Thibaud.Chatelet@sanofi.com ----------------------------
- Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis, from 1:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  1:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: SNY
  
  Form 10-Q for the quarterly period ended September 30, 2024. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Nov 1, 2024
- DJ Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates, from 3:05PM ET on Friday Nov 01, 2024 by Dow Jones
  3:05PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: SNY, VIR
  
  By Jasmine Li
  
  Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer.
  
  The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year.
Oct 29, 2024
- Sanofi Partners with SandboxAQ on AI-Driven Drug Discovery, from 3:37PM ET on Tuesday Oct 29, 2024 by MT Newswires
  3:37PM ET on Tuesday Oct 29, 2024 by MT Newswires
  Companies Mentioned: SNY
  03:37 PM EDT, 10/29/2024 (MT Newswires) -- Sanofi (SNY) selected SandboxAQ to identify biomarkers during clinical development, SandboxAQ said Tuesday. The partnership will use SandboxAQ's quantitative artificial intelligence models to causally filte...

Today
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN, from 4 hours ago by PR Newswire
  4 hours ago by PR Newswire
  Companies Mentioned: AZN
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: AZN
- DJ As Trump Readies a Reset of Antitrust Policy, Look to These Sectors for Deals -- Heard of the Street -- WSJ, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: HUM, MSFT, PFE, IRBT, AAPL, ADBE, AMGN, AMZN, META, BMY, DIS
Nov 8, 2024
- S&P 500 Closes Just Shy of Record 6,000 Amid Strong Post-Election Rally, from 4:55PM ET on Friday Nov 08, 2024 by MT Newswires
  4:55PM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: HD, CSCO, SPGI, VTRS, TSLA, WBD, MRNA, AZN, PLTR, CE, DIS, MTCH
- AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC, from 12:46PM ET on Friday Nov 08, 2024 by Dow Jones
  12:46PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: AZN
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN, from 12:05PM ET on Friday Nov 08, 2024 by Dow Jones
  12:05PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: AZN
- DJ AstraZeneca PLC Stock Rises Friday, Outperforms Market, from 12:01PM ET on Friday Nov 08, 2024 by Dow Jones
  12:01PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: AZN
- TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones
  7:00AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: AZN
- Amgen's Chronic Rhinosinusitis Drug Meets Main, Secondary Goals in Phase 3 Trial, from 4:54AM ET on Friday Nov 08, 2024 by MT Newswires
  4:54AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: AMGN, AZN
Nov 7, 2024
- ATTENTION AZN SHAREHOLDERS: Investors who lost money on AstraZeneca PLC are urged to contact Levi & Korsinsky about an ongoing investigation, from 3:31PM ET on Thursday Nov 07, 2024 by Dow Jones
  3:31PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: AZN

Sanofi SA
NASDAQ:SNYUnited States

Search Criteria

Nov 6, 2024

Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment, from 4:13AM ET on Wednesday Nov 06, 2024 by MT Newswires

Dupixent(R) (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis, from 1:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis, from 1:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

Nov 1, 2024

DJ Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates, from 3:05PM ET on Friday Nov 01, 2024 by Dow Jones

Oct 29, 2024

Sanofi Partners with SandboxAQ on AI-Driven Drug Discovery, from 3:37PM ET on Tuesday Oct 29, 2024 by MT Newswires

Peers Headlines

Today

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN, from 4 hours ago by PR Newswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN, from 4 hours ago by Dow Jones

DJ As Trump Readies a Reset of Antitrust Policy, Look to These Sectors for Deals -- Heard of the Street -- WSJ, from 9 hours ago by Dow Jones

Nov 8, 2024

S&P 500 Closes Just Shy of Record 6,000 Amid Strong Post-Election Rally, from 4:55PM ET on Friday Nov 08, 2024 by MT Newswires

AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC, from 12:46PM ET on Friday Nov 08, 2024 by Dow Jones

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN, from 12:05PM ET on Friday Nov 08, 2024 by Dow Jones

DJ AstraZeneca PLC Stock Rises Friday, Outperforms Market, from 12:01PM ET on Friday Nov 08, 2024 by Dow Jones

TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps, from 7:00AM ET on Friday Nov 08, 2024 by Dow Jones

Amgen's Chronic Rhinosinusitis Drug Meets Main, Secondary Goals in Phase 3 Trial, from 4:54AM ET on Friday Nov 08, 2024 by MT Newswires

Nov 7, 2024

ATTENTION AZN SHAREHOLDERS: Investors who lost money on AstraZeneca PLC are urged to contact Levi & Korsinsky about an ongoing investigation, from 3:31PM ET on Thursday Nov 07, 2024 by Dow Jones